Tevogen Bio Holdings Inc. Responds to Increased Shareholder Interest
Tevogen Bio Holdings Inc. is taking significant steps to engage with its shareholders. Recently, the company observed a surge in inquiries regarding its Direct Registration System (DRS). As a leading biopharmaceutical firm, Tevogen has recognized the importance of providing shareholders with secure options for owning their shares.
Understanding the Direct Registration System (DRS)
The Direct Registration System offers shareholders a straightforward and secure way to own their shares without needing a physical stock certificate. This system allows shares to be held in electronic form, simplifying the transfer and management process. For Tevogen, a company noted for its innovative approaches, this mode of share ownership aligns perfectly with their commitment to transparency and accessibility.
Why Shareholders Prefer DRS
Many of Tevogen's largest stakeholders, both internal and external, have opted to utilize the DRS. This choice reflects their confidence in the security and efficiency of this system. By holding shares directly in a DRS account, they can easily transfer ownership, streamline transactions, and eliminate the risks associated with physical certificates.
Step-by-Step Guidance for Shareholders
To assist shareholders in transitioning their holdings to a DRS account, Tevogen plans to release comprehensive guidance. This step-by-step process will be available shortly, aimed at making the transition seamless for all investors interested in registering their shares directly. The instructions will offer clarity on how to engage with Tevogen's transfer agent, Continental Stock Transfer & Trust, ensuring that shareholders can feel confident in their transition.
About Tevogen Bio Holdings Inc.
Tevogen is a biopharmaceutical company specializing in developing innovative therapies that leverage the power of the immune system. With a clear mission to enhance the quality of life through advanced medical solutions, the firm is dedicated to transparency and shareholder engagement. As it continues to grow and evolve, Tevogen remains committed to providing its shareholders with valuable information that supports informed decision-making.
Contacts for Shareholder Inquiries
For those who have questions regarding the DRS or require further assistance, Tevogen Bio Communications is available. You can reach them at:
- **Phone**: 1 877 TEVOGEN, Ext 701
- **Email**: Communications@Tevogen.com
Frequently Asked Questions
What is the Direct Registration System (DRS)?
The DRS is a method that allows shareholders to own their shares in electronic form rather than holding physical certificates, making transfers easier.
Why should I consider registering my shares through DRS?
DRS provides a secure and efficient way to manage your shares, reducing risks associated with physical certificates and simplifying ownership transfers.
How can I transfer my shares to a DRS account?
Tevogen will provide detailed instructions on how to transfer shares to a DRS account, ensuring a smooth transition for shareholders.
Who can help me with DRS-related questions?
Tevogen Bio Communications is available to assist with any inquiries related to DRS and can be contacted through phone or email.
Has the DRS been popular among Tevogen’s shareholders?
Yes, several of Tevogen's major shareholders have opted to utilize DRS, which showcases trust in this method of ownership.
